Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy

BACKGROUND: Patients with cancer are at increased risk of drug-drug interactions (DDI), which can increase treatment toxicity or decrease efficacy. It is especially important to thoroughly screen DDI in oncology clinical trial subjects to ensure trial subject safety and data accuracy. This study det...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcath, Lauren A., Finley, Colin M., Wong, Siu Fun, Hertz, Daniel L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995697/
https://www.ncbi.nlm.nih.gov/pubmed/33771105
http://dx.doi.org/10.1186/s12885-021-08050-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995697/
https://www.ncbi.nlm.nih.gov/pubmed/33771105
http://dx.doi.org/10.1186/s12885-021-08050-w

Ejemplares similares